Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ENvue Medical filings document the public-company reporting, capital structure, governance, and material agreements of a commercial-stage medical device issuer focused on enteral care and guided feeding tube placement. Recent disclosures include a Form 12b-25 notification related to the timing of the company's annual Form 10-K and the review of financial-statement information.
Material-event filings also cover amendments to employment and equity-award arrangements through ENvue Medical Israel, Ltd., a wholly owned subsidiary, and changes to the rights of holders of the company's Series H Convertible Preferred Stock. These records describe certificate-of-designation amendments, preferred-stock terms, securities-holder rights, and related corporate-governance actions.
ENvue Medical, Inc. registers the resale by a selling stockholder of up to 6,000,768 shares of common stock issuable upon conversion of 6,254 shares of Series H Convertible Preferred Stock at a current conversion price of $1.0422. The company will not receive proceeds from resales. As of April 30, 2026, 5,246,513 shares were outstanding; issuance of the full Conversion Shares would represent approximately 53.4% of outstanding shares as of that date. The prospectus notes Nasdaq listing risks, anti-dilution mechanics, cumulative dividend terms on the Series H, and broad resale methods permitted for the selling holder.
ENvue Medical, Inc. reported a significantly weaker quarter for the three months ended March 31, 2026, with revenues of $653,000 compared with $1,025,000 a year earlier, mainly due to the removal of its higher-margin PainShield Ultra product from the market.
The company generated a gross loss of $55,000 versus a gross profit of $369,000 last year, as margins were pressured by inventory write-downs and amortization of intangibles from the ENvue merger. Operating expenses rose to $3.7 million, driven by higher selling, marketing, and general and administrative costs tied to integrating and commercializing ENvue’s enteral feeding systems.
Net loss widened to $3.8 million, while net loss available to common stockholders reached $22.6 million after recognizing large deemed dividends and down-round adjustments on Series H preferred stock. Cash and cash equivalents fell to $2.2 million, with $4.3 million used in operating activities during the quarter, and the company discloses substantial doubt about its ability to continue as a going concern without additional financing.
ENvue Medical, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company stated it needs additional time to prepare and analyze supporting documentation and anticipates filing the Form 10-Q no later than the fifth calendar day following the prescribed due date. The notice was signed by CEO Doron Besser, M.D. on May 15, 2026.
ENvue Medical, Inc. insider Christian Michael Glibert filed a Form 4 showing no change in his share count, while his beneficial ownership percentage dropped below 10 percent. He continues to hold 240,000 shares of Common Stock directly. The footnote explains that his reduced percentage resulted from dilution after ENvue issued additional shares in connection with a merger described in its Form 10-K, meaning no shares were acquired or disposed of by him.
Christian Michael Glibert reports an updated beneficial ownership position in ENvue Medical, Inc. common stock. He continues to hold 240,000 shares, which now represent 6.5% of the company’s outstanding common stock.
The change in percentage results from ENvue Medical’s total shares outstanding increasing from 1,088,192 to 3,700,908, as disclosed in the company’s Annual Report on Form 10‑K filed on April 15, 2026. Glibert has not acquired or disposed of any shares since his initial Schedule 13D filed on February 11, 2026 and states he holds the position for investment purposes, while reserving the option to buy or sell shares in the future depending on market conditions.
ENvue Medical, Inc., formerly NanoVibronix, filed its annual report describing a major 2025 merger and a shift to a dual-business medical device model. The company acquired ENvue Medical Holdings, adding an enteral feeding navigation platform alongside its legacy ultrasound-based PainShield and UroShield therapies.
Following the merger, ENvue operates through Israeli subsidiary Nano OpCo for pain and biofilm-related devices, and ENvue Medical Holdings LLC for electromagnetic navigation-guided enteral feeding systems and related disposables. The company executed 1‑for‑11 and 1‑for‑10 reverse stock splits in 2025 and reported approximately $7.3 million aggregate market value of voting stock held by non‑affiliates and 3,700,908 common shares outstanding.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.